Literature DB >> 23639557

Negative predictive value of surveillance PET/CT in head and neck squamous cell cancer.

M McDermott1, M Hughes, T Rath, J T Johnson, D E Heron, G J Kubicek, S W Kim, R L Ferris, U Duvvuri, J P Ohr, B F Branstetter.   

Abstract

BACKGROUND AND
PURPOSE: Optimizing the utilization of surveillance PET/CT in treated HNSCC is an area of ongoing research. Our aim was to determine the negative predictive value of PET/CT in patients with treated head and neck squamous cell cancer and to determine whether negative PET/CT reduces the need for further imaging surveillance.
MATERIALS AND METHODS: We evaluated patients with treated HNSCC who underwent posttreatment surveillance PET/CT. During routine clinical readouts, scans were categorized as having negative, probably negative, probably malignant, or malignant findings. We followed patients clinically and radiographically for at least 12 months from their last PET/CT (mean, 26 months; median, 28 months; range, 12-89 months) to determine recurrence rates. All suspected recurrences underwent biopsy for confirmation.
RESULTS: Five hundred twelve patients (1553 scans) were included in the study. Two hundred fourteen patients had at least 1 PET/CT with negative findings. Of the 214 patients with a scan with negative findings, 19 (9%) eventually experienced recurrence, resulting in a NPV of 91%. In addition, a subgroup of 114 patients with 2 consecutive PET/CT examinations with negative findings within a 6-month period was identified. Only 2 recurrences were found in this group, giving a NPV of 98%.
CONCLUSIONS: In patients treated for HNSCC, a single PET/CT with negative findings carries a NPV of 91%, which is not adequate to defer further radiologic surveillance. Two consecutive PET/CT examinations with negative findings within a 6-month period, however, resulted in a NPV of 98%, which could obviate further radiologic imaging in the absence of clinical signs of recurrence.

Entities:  

Mesh:

Year:  2013        PMID: 23639557      PMCID: PMC8051472          DOI: 10.3174/ajnr.A3494

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  15 in total

1.  Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers.

Authors:  Regiane S Andrade; Dwight E Heron; Berna Degirmenci; Pedro A A Filho; Barton F Branstetter; Raja R Seethala; Robert L Ferris; Norbert Avril
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-06-05       Impact factor: 7.038

2.  Value of FDG PET in assessment of treatment response and surveillance in head-and-neck cancer patients after intensity modulated radiation treatment: a preliminary report.

Authors:  Min Yao; Michael M Graham; Russell B Smith; Kenneth J Dornfeld; Mark Skwarchuk; Henry T Hoffman; Gerry F Funk; Scott M Graham; Yusuf Menda; John M Buatti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-12-01       Impact factor: 7.038

3.  The use of combined PET/CT for localizing recurrent head and neck cancer: the Pittsburgh experience.

Authors:  Lee A Zimmer; Carl Snyderman; Melanie B Fukui; Todd Blodgett; Barry McCook; David W Townsend; Carolyn C Meltzer
Journal:  Ear Nose Throat J       Date:  2005-02       Impact factor: 1.697

4.  Temporal patterns of head and neck squamous cell carcinoma recurrence with positron-emission tomography/computed tomography monitoring.

Authors:  Daniel M Beswick; William E Gooding; Jonas T Johnson; Barton F Branstetter
Journal:  Laryngoscope       Date:  2012-06-08       Impact factor: 3.325

5.  Head and neck malignancy: is PET/CT more accurate than PET or CT alone?

Authors:  Barton F Branstetter; Todd M Blodgett; Lee A Zimmer; Carl H Snyderman; Jonas T Johnson; Subha Raman; Carolyn C Meltzer
Journal:  Radiology       Date:  2005-05       Impact factor: 11.105

6.  Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer.

Authors:  Sandro V Porceddu; Elizabeth Jarmolowski; Rodney J Hicks; Rob Ware; LeAnn Weih; Danny Rischin; June Corry; Lester J Peters
Journal:  Head Neck       Date:  2005-03       Impact factor: 3.147

7.  Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for Locoregional advanced head and neck cancer.

Authors:  Seng Chuan Ong; Heiko Schöder; Nancy Y Lee; Snehal G Patel; Diane Carlson; Matthew Fury; David G Pfister; Jatin P Shah; Steven M Larson; Dennis H Kraus
Journal:  J Nucl Med       Date:  2008-03-14       Impact factor: 10.057

8.  Positron emission tomography in the early follow-up of advanced head and neck cancer.

Authors:  Gerhard W Goerres; Daniel T Schmid; Florian Bandhauer; Pia U Huguenin; Gustav K von Schulthess; Stephan Schmid; Sandro J Stoeckli
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2004-01

9.  Deferring planned neck dissection following chemoradiation for stage IV head and neck cancer: the utility of PET-CT.

Authors:  Jayakar V Nayak; Rohan R Walvekar; Regiane S Andrade; Nicole Daamen; Stephen Y Lai; Athanassios Argiris; Ryan P Smith; Dwight E Heron; Robert L Ferris; Jonas T Johnson; Barton F Branstetter
Journal:  Laryngoscope       Date:  2007-12       Impact factor: 3.325

Review 10.  Indications for PET/CT in the head and neck.

Authors:  Vikas Agarwal; Barton F Branstetter; Jonas T Johnson
Journal:  Otolaryngol Clin North Am       Date:  2008-02       Impact factor: 3.346

View more
  17 in total

1.  Posttreatment Imaging in Patients with Head and Neck Cancer without Clinical Evidence of Recurrence: Should Surveillance Imaging Extend Beyond 6 Months?

Authors:  A Gore; K Baugnon; J Beitler; N F Saba; M R Patel; X Wu; B J Boyce; A H Aiken
Journal:  AJNR Am J Neuroradiol       Date:  2020-06-18       Impact factor: 3.825

2.  Usefulness of surveillance imaging in patients with head and neck cancer who are treated with definitive radiotherapy.

Authors:  Sweet Ping Ng; Courtney Pollard; Joel Berends; Zeina Ayoub; Mona Kamal; Adam S Garden; Houda Bahig; Scott B Cantor; Andrew J Schaefer; Temitayo Ajayi; G Brandon Gunn; Steven J Frank; Heath Skinner; Jack Phan; William H Morrison; Renata Ferrarotto; Jason M Johnson; Abdallah S R Mohamed; Stephen Y Lai; Amy C Hessel; Erich M Sturgis; Randal S Weber; Clifton D Fuller; David I Rosenthal
Journal:  Cancer       Date:  2019-02-12       Impact factor: 6.860

3.  FDG-PET/contrast-enhanced CT as a post-treatment tool in head and neck squamous cell carcinoma: comparison with FDG-PET/non-contrast-enhanced CT and contrast-enhanced CT.

Authors:  Yuko Suenaga; Kazuhiro Kitajima; Takeaki Ishihara; Ryohei Sasaki; Naoki Otsuki; Ken-Ichi Nibu; Tsutomu Minamikawa; Naomi Kiyota; Kazuro Sugimura
Journal:  Eur Radiol       Date:  2015-07-19       Impact factor: 5.315

Review 4.  The role of PET/CT in the management of patients affected by head and neck tumors: a review of the literature.

Authors:  Giovanni Cammaroto; Natale Quartuccio; Alessandro Sindoni; Francesca Di Mauro; Federico Caobelli
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-05-14       Impact factor: 2.503

5.  Initial Performance of NI-RADS to Predict Residual or Recurrent Head and Neck Squamous Cell Carcinoma.

Authors:  D A Krieger; P A Hudgins; G K Nayak; K L Baugnon; A S Corey; M R Patel; J J Beitler; N F Saba; Y Liu; A H Aiken
Journal:  AJNR Am J Neuroradiol       Date:  2017-03-31       Impact factor: 3.825

6.  Perceived value drives use of routine asymptomatic surveillance PET/CT by physicians who treat head and neck cancer.

Authors:  Benjamin R Roman; Shivangi Lohia; Nandita Mitra; Marilene B Wang; Anna M Pou; F Christopher Holsinger; David Myssiorek; David Goldenberg; David A Asch; Judy A Shea
Journal:  Head Neck       Date:  2020-01-10       Impact factor: 3.147

7.  Evaluating the potential role of PET/CT in the posttreatment surveillance of head and neck cancer.

Authors:  Shrujal S Baxi; Lara Dunn; David G Pfister
Journal:  J Natl Compr Canc Netw       Date:  2015-03       Impact factor: 11.908

8.  Positive Predictive Value of Neck Imaging Reporting and Data System Categories 3 and 4 Posttreatment FDG-PET/CT in Head and Neck Squamous Cell Carcinoma.

Authors:  P Wangaryattawanich; B F Branstetter; J D Ly; U Duvvuri; D E Heron; T J Rath
Journal:  AJNR Am J Neuroradiol       Date:  2020-05-28       Impact factor: 3.825

Review 9.  Role of (18)F-FDG PET/CT in pre and post treatment evaluation in head and neck carcinoma.

Authors:  Bundhit Tantiwongkosi; Fang Yu; Anand Kanard; Frank R Miller
Journal:  World J Radiol       Date:  2014-05-28

Review 10.  Application of fluorodeoxyglucose positron emission tomography in the management of head and neck cancers.

Authors:  Farzan Siddiqui; Min Yao
Journal:  World J Radiol       Date:  2014-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.